Taxotere (Doxetaxel) is a chemotherapy drug manufactured and marketed by Sanofi-Avents. Doctors prescribe the drug to treat the majority of breast cancer cases in the U.S. The treatment plan for Taxotere is once every three weeks, unlike Paclitaxel, a drug in the same class, which is weekly and just as effective. The Taxotere lawsuit states that Sanofi-Aventis failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair) through the use of Taxotere during chemotherapy. Sanofi-Aventis warned other countries about alopecia risk but did not warn women in the U.S. If properly warned of the risks associated with Taxotere, patients would have been prescribed a different chemotherapy drug that did not result in permanent hair loss.